Entrada Therapeutics, Inc. (TRDA) Dividend History

Entrada Therapeutics, Inc. is a biotechnology company focused on developing intracellular biologic therapies. Utilizing its proprietary platform, the company aims to create innovative treatments for diseases with high unmet medical needs by delivering therapeutic molecules directly into cells.

One Design Center Place, Boston, MA, 02210
Phone: 857-305-1825
Website: https://www.entradatx.com

Dividend History

Entrada Therapeutics, Inc. currently does not pay dividends

Company News

  • Entrada Therapeutics announced the recipients of its second annual DREAMS Grant Program, awarding $25,000 each to three U.S. non-profit organizations - CureDuchenne, The Little Hercules Foundation, and Walking Strong - to support programs advancing diversity, equity, inclusion, and accessibility within the Duchenne community.

    GlobeNewswire Inc.
  • Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.

    Zacks Investment Research
    Featured Companies: EXAS LLY NKTR
  • Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. HCI Group The Trade: HCI Group Inc (NYSE: HCI) CEO Paresh Patel acquired a total of 1,000 shares an average ...

    Benzinga
    Featured Companies: CRMT HCI
Page data last updated 07/23/2025 16:43:59 UTC